{"id":123142,"date":"2026-03-08T07:03:09","date_gmt":"2026-03-08T07:03:09","guid":{"rendered":"https:\/\/www.europesays.com\/lt\/123142\/"},"modified":"2026-03-08T07:03:09","modified_gmt":"2026-03-08T07:03:09","slug":"moderna-issprende-viena-didziausiu-problemu-bet-bendrovei-tai-kainuos-milijonus","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/lt\/123142\/","title":{"rendered":"\u201eModerna\u201c i\u0161sprend\u0117 vien\u0105 did\u017eiausi\u0173 problem\u0173, bet bendrovei tai kainuos milijonus"},"content":{"rendered":"<p>\u201eModerna\u201c sutiko sumok\u0117ti 950 mln. <a data-autolink-id=\"9\" target=\"_blank\" href=\"https:\/\/ekonomika.lt\/temos\/jav\/\" title=\"JAV\" rel=\"nofollow noopener\">JAV<\/a> doleri\u0173, kad u\u017ebaigt\u0173 ilgai trukus\u012f patentin\u012f gin\u010d\u0105 d\u0117l technologijos, naudotos jos COVID-19 vakcinoje.<\/p>\n<p>Farmacijos mil\u017ein\u0117 prane\u0161\u0117 pasiekusi visuotin\u012f susitarim\u0105 su \u201eArbutus Biopharma\u201c ir \u201eGenevant Sciences GmbH\u201c d\u0117l kaltinim\u0173, es\u0105 \u201eModerna\u201c vakcinos pa\u017eeid\u0117 patentus, susijusius su lipidini\u0173 nanodaleli\u0173 (LNP) pristatymo technologija.<\/p>\n<p>\u0160ios ma\u017eos riebal\u0173 pagrindu sukurtos dalel\u0117s naudojamos mRNR vakcinoms perne\u0161ti \u012f \u017emogaus l\u0105steles.<\/p>\n<p>Pagal susitarim\u0105 \u201eModerna\u201c 2026 met\u0173 tre\u010di\u0105j\u012f ketvirt\u012f i\u0161mok\u0117s vienkartin\u0119 950 mln. JAV doleri\u0173 sum\u0105. Bendrovei taip pat nereik\u0117s mok\u0117ti autorini\u0173 atlyginim\u0173 nei u\u017e esamas, nei u\u017e b\u016bsimas vakcinas. \u0160is susitarimas u\u017ebaigia visus su \u0161iomis bendrov\u0117mis susijusius teisminius gin\u010dus visame pasaulyje.<\/p>\n<p>Bylos esm\u0117 buvo kaltinimai, kad \u201eModerna\u201c savo COVID-19 vakcinoje be leidimo naudojo \u201eArbutus Biopharma\u201c ir \u201eGenevant Sciences GmbH\u201c priklausan\u010di\u0105 LNP technologij\u0105.<\/p>\n<p>\u201e\u0160io i\u0161 pandeminio laikotarpio paveld\u0117to klausimo i\u0161sprendimas pa\u0161alina neapibr\u0117\u017etum\u0105 ir leid\u017eia vis\u0105 d\u0117mes\u012f sutelkti \u012f \u012fdomias artimiausios ateities \u201eModerna\u201c perspektyvas\u201c, \u2013 teig\u0117 \u201eModerna\u201c vadovas St\u00e9phane\u2019as Bancelis.\n                    <\/p>\n<p>\u201eModerna\u201c taip pat nurod\u0117 toliau sieksianti apeliacijos d\u0117l savo argumento, susijusio su JAV teis\u0117je numatytu vyriausyb\u0117s rangovo imunitetu, kuris gal\u0117t\u0173 dar labiau apriboti bendrov\u0117s atsakomyb\u0119.<\/p>\n<p>Jei Federalinis apeliacinis teismas \u0161iuo klausimu galiausiai priimt\u0173 bendrovei nepalank\u0173 sprendim\u0105, \u201eModerna\u201c per 90 dien\u0173 nuo sprendimo pri\u0117mimo gal\u0117t\u0173 b\u016bti \u012fpareigota sumok\u0117ti papildomai iki 1,3 mlrd. JAV doleri\u0173. Bendrov\u0117 teig\u0117 kol kas neu\u017efiksavusi papildom\u0173 su tuo susijusi\u0173 i\u0161laid\u0173, nes nemano, kad toks scenarijus yra tik\u0117tinas.<\/p>\n<p>\u201eModerna\u201c tikisi 2026 met\u0173 pirm\u0105j\u012f ketvirt\u012f apskaityti 950 mln. JAV doleri\u0173 i\u0161laidas, susijusias su \u0161iuo susitarimu.<\/p>\n<p>Nepaisant numatytos i\u0161mokos, bendrov\u0117 prognozuoja, kad 2026 met\u0173 pabaigoje tur\u0117s nuo 4,5 mlrd. iki 5 mlrd. JAV doleri\u0173 gryn\u0173j\u0173 pinig\u0173 ir j\u0173 ekvivalent\u0173. \u012eskaitant prieig\u0105 prie kredito linijos, bendras prieinamo likvidumo lygis, bendrov\u0117s vertinimu, sieks nuo 5,4 mlrd. iki 5,9 mlrd. JAV doleri\u0173.<\/p>\n<p>Investuotojai \u012f \u0161io gin\u010do i\u0161sprendim\u0105 reagavo palankiai. Analitik\u0173 teigimu, tai pa\u0161alina vien\u0105 did\u017eiausi\u0173 neapibr\u0117\u017etum\u0173, sl\u0117gusi\u0173 bendrov\u0119. Po prane\u0161imo paskelbimo \u201eModerna\u201c akcij\u0173 kaina prie\u0161bir\u017ein\u0117je prekyboje buvo pakilusi net iki 10 proc., o \u201eArbutus Biopharma\u201c akcijos smuko.\n                    <\/p>\n<p>Nors susitarimas u\u017ebaigia \u201eModerna\u201c gin\u010d\u0105 su \u201eArbutus Biopharma\u201c ir \u201eGenevant Sciences GmbH\u201c, bendrov\u0117 vis dar dalyvauja kituose intelektin\u0117s nuosavyb\u0117s teisminiuose procesuose.<\/p>\n<p>\u201eModerna\u201c t\u0119sia teisinius gin\u010dus su \u201ePfizer\u201c ir \u201eBioNTech SE\u201c d\u0117l mRNR technologijos, naudotos konkuruojan\u010diose COVID-19 vakcinose.\n<\/p>\n<p>\n\t\t\t\tKaip vertinate \u0161\u012f \u012fra\u0161\u0105?\n\t\t\t<\/p>\n","protected":false},"excerpt":{"rendered":"\u201eModerna\u201c sutiko sumok\u0117ti 950 mln. JAV doleri\u0173, kad u\u017ebaigt\u0173 ilgai trukus\u012f patentin\u012f gin\u010d\u0105 d\u0117l technologijos, naudotos jos COVID-19&hellip;\n","protected":false},"author":2,"featured_media":123143,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[17],"tags":[81,1115,1431,37,39,36,38,40,22466,255,46],"class_list":["post-123142","post","type-post","status-publish","format-standard","has-post-thumbnail","category-verslas","tag-business","tag-covid-19","tag-gincas","tag-lietuva","tag-lietuviu","tag-lithuania","tag-lithuanian","tag-lt","tag-moderna","tag-teismas","tag-verslas"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lt\/116192280781580113","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/123142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/comments?post=123142"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/123142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media\/123143"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media?parent=123142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/categories?post=123142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/tags?post=123142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}